08:20 AM EDT, 09/18/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use on Thursday recommended the approval of Zentiva's Ruxolitinib Zentiva, a generic version of Jakavi, according to a Friday notice. The marketing authorization application covers the use of Ruxolitinib Zentiva for treating myelofibrosis, polycythaemia vera, and graft-versus-host disease. The drug contains the active substance ruxolitinib and will be available as 5-milligram, 10-mg, 15-mg, and 20-mg tablets. The European Commission will now make its decision on the treatment based on the recommendation.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.